Synapse - Department of Medicine

Results (39669)

Phase II trial of dose-dense R-CHOP followed by risk-adapted consolidation with either ICE or ICE and ASCT, based upon the results of biopsy confirmed abnormal interim restaging PET scan, improves outcome in patients with advanced stage DLBCL

Meeting Abstract

Moskowitz, C.; Hamlin, P. A.; Horwitz, S. M.; Noy, A.; O'Connor, O. A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; Lessac-Chenen, S.; Weaver, A.; more...
Blood (2006)

Fulltext@MSK | Save

Phase 2 trial of (177)Lutetium (Lu-177) radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody (mAb) J591 (Lu-177-J591) in patients (pts) with metastatic androgen-independent prostate cancer (AIPC)

Meeting Abstract

Morris, M. J.; Milowsky, M. I.; Pandit-Taskar, N.; Divgi, C.; David, K. A.; Rozario, C. P.; Vallabhajosula, S.; Goldsmith, S. J.; Scher, H. I.; Nanus, D. M.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Phase 2 trial of trastuzumab (T) and KOS-953 (17-AAG) in patients (pts) with Her2-positive breast cancer: Preliminary results

Meeting Abstract

Modi, S.; Stopeck, A.; Linden, H. M.; Sugarman, S.; Ma, W.; Solit, D.; Rosen, N.; Kersey, K.; Johnson, R. G.; Hannah, A. L.; more...
Breast Cancer Research and Treatment (2006)

Fulltext@MSK | Save

Phase I trial of KOS-953, a heat shock protein 90 inhibitor, and trastuzumab (T)

Meeting Abstract

Modi, S.; Stopeck, A.; Gordon, M. S.; Solit, D.; Ma, W.; Wheler, J.; Cropp, G.; Johnson, R. G.; Hannah, A. L.; Hudis, C.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

EGFR mutation and copy number, EGFR protein expression and KRAS mutation as predictors of outcome with erlotinib in bronchioloalveolar cell carcinoma (BAC): Results of a prospective phase II trial

Meeting Abstract

Miller, V. A.; Zakowski, M.; Riely, G. J.; Pao, W.; Ladanyi, M.; Tsao, A. S.; Sandler, A.; Herbst, R.; Kris, M. G.; Johnson, D. H.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

Phase I/II trial of the prostate-specific membrane antigen (PSMA)-targeted immunoconjugate MLN2704 in patients (pts) with progressive metastatic castration resistant prostate cancer (CRPC)

Meeting Abstract

Milowsky, M. I.; Galsky, M.; George, D. J.; Lewin, J. M.; Rozario, C. P.; Marshall, T.; Chang, M.; Nanus, D. M.; Webb, I. J.; Scher, H. I.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save

KLHDC8B is a novel, mitotically-regulated classical Hodgkin's lymphoma candidate susceptibility gene

Meeting Abstract

Mealiffe, M. E.; Kirchhoff, T.; Wiernik, P. H.; Lynch, H. T.; Daibata, M.; Gerdes, A. M.; Offit, K.; Goldin, L. R.; Horwitz, M. S.
Blood (2006)

Fulltext@MSK | Save

CD4+peptide epitopes from the WT1 oncoprotein stimulate CD4+and CD8+T cells that recognize and kill leukemia and solid tumor cells

Meeting Abstract

May, R. J.; Pinilla, J.; Korontsvit, T.; Zakhaleva, V.; Zhang, R. H.; Dao, T.; Maslak, P.; Scheinberg, D. A.
Blood (2006)

Fulltext@MSK | Save

Correlative results of in-vivo monitoring of platelet-derived growth factor receptor (PDGFR) activation status in a randomized placebo-controlled trial of docetaxel +/- imatinib in castration-resistant prostate cancer (CRPC) and bone metastases (BM)

Meeting Abstract

Mathew, P.; Thall, P. F.; Wen, S.; Horne, E.; Johnson, M.; Oh, W. K.; Morris, M. J.; Logothetis, C. J.; Fidler, I. J.; Bucana, C.
EJC Supplements (2006)

Fulltext@MSK | Save

Preliminary results of a randomized placebo-controlled,double-blind trial of weekly docetaxel combined with imatinib in men with metastatic androgen-independent prostate cancer (AIPC) and bone metastases (BM)

Meeting Abstract

Mathew, P.; Thall, P. F.; Johnson, M. M.; Oh, W. K.; Meluch, A. A.; Morris, M. J.; Troncoso, P.; Bucana, C. D.; Fidler, I. J.; Logothetis, C. J.
Journal of Clinical Oncology (2006)

Fulltext@MSK | Save